Getting specific on sepsis

Many of the failed efforts to develop sepsis drugs have focused on broad inflammatory modulators. In fact, the only product to date that has shown success in Phase III trials that measure 28 day mortality is Eli Lilly and Co.'s Zovant, a serine protease that works by both anticoagulant and anti-inflammatory mechanisms. Last week, investigators at F. Hoffmann-La Roche reported in Nature the identification

Read the full 649 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE